Bristol-Myers Squibb news

BMY receives a Zacks Rank #2 (Buy) with a Value grade of A. It has attractive valuation metrics including a forward P/E of 9.10, PEG ratio of 0.30, and P/B ratio of 5.75, indicating positive earnings estimate revisions and undervaluation relative to peers.

Positive Phase II trial results for arlo-cel meeting primary endpoints, potential first-in-class therapy targeting GPRC5D, recent FDA approval of Zenbexus, stock up 19.9% year-to-date, and strengthened long-term pipeline for multiple myeloma treatment.

Strong five-year clinical data demonstrating durability and efficacy of Camzyos, robust 74% YoY sales growth, FDA Priority Review for adolescent indication, and established market position in cardiac myosin inhibitor space support positive outlook.

Trading at significant valuation discount (P/E 14.24 vs AbbVie's 70.92) with solid net income recovery ($7.1B), but facing headwinds from patent cliff on blockbuster drugs (Eliquis, Opdivo), flat revenue growth (-0.2% YoY), and ongoing pricing pressure. Recovery case exists but uncertainty remains.

Bristol-Myers' deucravacitinib was shown to be inferior to Takeda's zasocitinib in direct comparison, with less than half the complete skin clearance response rate, potentially impacting market share in the plaque psoriasis treatment segment.

The company is making significant strategic investments in AI to enhance drug discovery and development processes, which should improve efficiency and success rates in bringing new medicines to market. Stock was trading higher on the announcement.

Company beat earnings expectations ($1.58 vs $1.42 estimate) and revenue guidance ($11.49B vs $10.91B estimate). Growth Portfolio showed strong 12% revenue growth. Stock price increased 4.44% on the news. Full-year guidance was reaffirmed, indicating management confidence despite some value concerns noted by analysts.

Company leads the Abecma market with recent European Commission approval (March 2024) for expanded patient population, strategic partnership with 2Seventy Bio to expand reach, and strong positioning in growing CAR T-cell therapy market driven by rising multiple myeloma incidence.

Company offers an attractive 4% dividend yield with a sustainable payout ratio of 70%, strong dividend growth history, and recovery potential as stock trades 25% below 2022 highs. While facing patent expiration challenges and market neglect due to GLP-1 hype, the company has proven ability to manage patent expirations and maintains a solid pipeline in cardiovascular, cancer, and immune-related medicines.

Despite near-term headwinds from patent expirations (Eliquis and Opdivo losing exclusivity by 2028), the company demonstrates strong execution with its growth portfolio increasing 15% YoY and new successful drug launches. The low valuation (P/E of 9) presents upside potential if turnaround efforts continue to succeed, with potential for re-rating to mid-teens multiples if 2027-2028 results exceed expectations.

Bristol Myers Squibb shows solid fundamentals with 4.1% dividend yield and a history of increasing dividends (raised to $0.63 quarterly in January 2026). Demonstrated resilience during previous rate-hike periods, suggesting ability to maintain dividends despite higher rates.

Major immunology manufacturer benefiting from growing adoption of biologics and targeted therapies in autoimmune disease treatment

Highlighted as a suitable dividend stock for retirees with a 4.05% dividend yield, significantly higher than the S&P 500's 1.40% and the industry average of 0%, plus 3.33% annualized dividend growth.

Bristol-Myers Squibb's ZENBEXUS demonstrated strong clinical efficacy with a 41% MRD-negative complete response rate, nearly double the comparator arm. The drug's approval and expanded distribution network through Onco360 represents successful commercialization of a novel therapeutic agent for multiple myeloma treatment.

Strong Q2 earnings beat, discounted valuation relative to peers, robust growth portfolio accounting for 60% of revenue with 15% YoY growth, substantial free cash flow generation ($3B+ in Q2), 17-year dividend increase streak with 3.95% yield, $5B buyback program, and potential acquisition interest from AstraZeneca all support bullish outlook despite patent expiration concerns.

Positive two-year clinical data demonstrating sustained efficacy and safety for Sotyktu, strong 24% YoY revenue growth, stock up 16.5% YTD, and multiple pipeline opportunities in lupus and Sjögren's disease represent significant growth drivers for the company's portfolio.

Offers attractive valuation (P/E 9.2x vs AbbVie's 18.5x) and strong net margins (14.6%), but faces headwinds including flat revenue growth (-0.2%), reliance on legacy products facing patent expiration, $6.7 billion Celgene acquisition lawsuit, and ongoing portfolio transition challenges. Downside risk is priced in but not an obvious buy.

Recommended as a dividend stock with a 3.96% yield, above S&P 500 average of 1.40%, and 3.33% annualized dividend growth, making it suitable for retirement income generation.

Listed among leading companies but lacks specific product mentions or recent developments that would indicate positive or negative sentiment.

Bristol Myers Squibb markets BREYANZI, which received FDA approval for marginal zone lymphoma in December 2025. The company is positioned in a growing market with expanding indications and earlier treatment line adoption.

Featured company with strong immunotherapy portfolio including checkpoint inhibitors and monoclonal antibodies, well-positioned for market expansion.

Identified as a top-3 holding in the ETF with no specific performance metrics or analysis provided.

Opdivo, Bristol Myers' competing PD-L1 inhibitor to Keytruda, generated $4.63 billion in first-half 2026 sales but declined 3.9% year-over-year, indicating market pressure from competition.

SOTYKTU achieved FDA approval for psoriatic arthritis as the first TYK2 inhibitor in this indication, expanding market potential. Strong clinical data with sustained efficacy rates (67%-73% PASI 75 response) and excellent safety profile (5,000+ patient-years with no new safety signals) support positive commercial outlook. Once-daily oral administration and large underpenetrated market opportunity position the drug favorably for revenue growth through 2034.

Listed as major key player in the monoclonal antibodies market with exposure to high-growth oncology and immunology applications.

Listed as a major key player in the competitive landscape but no specific recent developments or achievements mentioned in the article.

Major pharmaceutical company positioned to benefit from drug repurposing opportunities in oncology and other therapeutic areas.

Identified as a major key player in the atopic dermatitis drugs market, but no specific product developments or competitive advantages highlighted in the article.

Bristol Myers Squibb is collaborating with BioNTech on pumitamig development. Its involvement is mentioned but not central to the comparative analysis or investment recommendation.